先天性长QT综合征患者植入式心律转复除颤器指南推荐不依从的频率与结局
该回顾性分析纳入2861例LQT1、LQT2或LQT3患者,识别出290例(约10%)符合2022年欧洲心脏病学会指南ICD推荐。其中156例(54%)未植入ICD,未植入组非致死性突破性心脏事件仅6例(4%),显著低于ICD组(P < .001);ICD组134例中55例(41%)发生至少1次适当的终止心室颤动的ICD治疗,13例(10%)发生ICD相关并发症。作者基于两个LQTS专科中心超过1200年联合随访的经验认为,许多符合2022年欧洲心脏病学会指南ICD推荐的患者可能并不需要ICD,尤其是因接受β受体阻滞剂治疗期间发生突破性心脏事件而获得推荐者或无症状但1-2-3-LQTS-Risk评分升高者。
要点
- 290例(约10%)符合2022年欧洲心脏病学会指南ICD推荐,其中156例(54%)未植入ICD。
- 未植入ICD组非致死性突破性心脏事件仅6/156(4%),显著低于ICD组(P < .001)。
- ICD组134例中55例(41%)发生至少1次适当的终止心室颤动的ICD治疗,13例(10%)发生ICD相关并发症。
- 作者认为,许多符合2022年欧洲心脏病学会指南ICD推荐的患者可能并不需要ICD。
- 作者认为,因接受β受体阻滞剂治疗期间发生突破性心脏事件而获得推荐者或无症状但1-2-3-LQTS-Risk评分升高者尤其可能不需要ICD。
适用人群与场景
- LQT1、LQT2或LQT3患者,共2861例,用于识别符合2022年欧洲心脏病学会指南ICD推荐的患者。
- 符合指南推荐并纳入比较的患者共290例(约10%),其中接受ICD者134例,未接受ICD者156例。
诊断标准与关键阈值
- 2022年欧洲心脏病学会指南基于ICD推荐:class I/level B 53例(18%)、class I/level C 56例(19%)、class IIa/level C 19例(7%)、class IIb/level B 162例(56%)。
研究设计与关键结果
- 回顾性分析2861例LQT1、LQT2或LQT3患者,识别出290例(约10%)符合2022年欧洲心脏病学会指南ICD推荐。
- 290例中53例(18%)为class I/level B推荐,56例(19%)为class I/level C推荐,19例(7%)为class IIa/level C推荐,162例(56%)为class IIb/level B推荐。
- 290例中156例(54%)未接受ICD。
- 接受ICD的134例中,55例(41%)发生至少1次适当的终止心室颤动的ICD治疗,13例(10%)发生ICD相关并发症。
- 未接受ICD的156例中,仅6例(4%)发生非致死性突破性心脏事件,显著低于ICD组(P < .001)。
- 两个LQTS专科中心联合随访超过1200年。
证据类型、等级与局限
- 证据类型:回顾性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,许多符合2022年欧洲心脏病学会指南ICD推荐的患者可能并不需要ICD。
- 作者认为,因接受β受体阻滞剂治疗期间发生突破性心脏事件而获得ICD推荐者或无症状但1-2-3-LQTS-Risk评分升高者,尤其可能不需要ICD。
指南或共识出处
- 2022年欧洲心脏病学会指南
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Guideline-directed device therapy for long QT syndrome (LQTS) has evolved during the years, and indications for an implantable cardioverter-defibrillator (ICD) vary between professional cardiac societies.
OBJECTIVE: We aimed to identify the subset of patients with LQTS who satisfied a class I or class II 2022 European Society of Cardiology guideline-based recommendation for an ICD and to determine the outcomes of those patients who received an ICD compared with those treated without an ICD.
METHODS: Retrospective analysis was conducted of 2861 patients with LQT1, LQT2, or LQT3 to identify patients meeting contemporary recommendations for guideline-directed device therapy. Basic demographics, clinical characteristics, and frequency/type of breakthrough cardiac events (BCEs) were extracted, and outcomes/complications were compared between patients treated with an ICD and those treated without one.
RESULTS: Of the 290 patients (approximately 10%) who met a guideline-based recommendation, 53 (18%) satisfied a class I/level B indication for an ICD; 56 (19%), a class I/level C indication; 19 (7%), a class IIa/level C indication; and 162 (56%), a class IIb/level B indication. However, most patients (156/290 [54%]) did not receive an ICD. Of those who received an ICD, 55 of 134 (41%) experienced ≥1 appropriate ventricular fibrillation-terminating ICD therapy, whereas ICD-related complications occurred in 13 patients (10%). Of those who were treated without an ICD, only 6 of 156 patients (4%) had nonlethal BCEs, which was significantly lower compared with the ICD group (P < .001).
CONCLUSION: With >1200 years of combined follow-up, the experience and evidence from our 2 LQTS specialty centers suggest that many patients who satisfy a recommendation for an ICD based on the latest 2022 European Society of Cardiology guidelines may not need one. This is particularly true when the indication stemmed from a BCE while receiving beta blocker therapy or in asymptomatic patients with an increased 1-2-3-LQTS-Risk score.
参考来源
- Neves R, Crotti L, Bains S, et al. Frequency of and outcomes associated with nonadherence to guideline-based recommendations for an implantable cardioverter-defibrillator in patients with congenital long QT syndrome. Heart Rhythm. 2024. PMID: 39366437. doi:10.1016/j.hrthm.2024.09.063
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。